CellSource Guides to a Full-Year Net Loss After a ¥174 Million Nine-Month Profit

A merger removed the year-earlier comparison

CellSource Co., Ltd. (TSE: 4880), the Tokyo-based regenerative-medicine company that processes blood-derived and fat-derived cells under contract for Japanese clinics, published results for the nine months to July 31, 2026 on September 8, 2026 under Japanese GAAP. Revenue was ¥2,557 million, gross profit ¥1,507 million, selling, general and administrative expenses ¥1,328 million, operating profit ¥179 million, ordinary profit ¥174 million, pre-tax profit ¥232 million and net profit ¥174 million, for earnings per share of ¥8.80 and ¥8.77 fully diluted. Every prior-year column in the profit and loss table is a dash. On July 1, 2026 the company absorbed its consolidated subsidiary Hybrid Medical Inc. and moved from consolidated to non-consolidated reporting from this third quarter; because this is the first year on a single-entity basis, the filing states no year-earlier profit figures and no growth rates against them.

The merger leaves three visible traces. Shares in affiliates fell to nil from ¥200.0 million as the subsidiary ceased to exist, intangible fixed assets rose ¥80.7 million to ¥137.1 million, and the income statement carries ¥65.6 million of gain on extinguishment of the merged subsidiary's shares in extraordinary income. Retained earnings rose ¥75.4 million over the nine months, which the company attributes mainly to that gain. The ¥99.1 million by which the ¥174.5 million of net profit exceeds that increase matches the ¥5.00 a share year-end dividend for FY10/2025, paid during the period on the 19,819,382 shares outstanding net of treasury.

More partner clinics, fewer procedures

The company runs a single reportable segment, the regenerative-medicine-related business, but discloses four service lines within it. Processing contracts produced ¥1,703.0 million, 66.6% of revenue; medical-device sales ¥610.4 million, or 23.9%, which the company says rose on higher sales to customers; cosmetics and other ¥186.1 million, or 7.3%, held back by weaker business-to-business cosmetics; and medical-institution support ¥58.0 million, or 2.3%, a line the merger enlarged. The operational story sits inside the first of those. The number of partner medical institutions holding a processing or support contract reached 2,218 at quarter-end, up 116 from the last fiscal year-end and up 35 in the quarter alone. But the count of blood-derived and adipose-stem-cell processing orders fell to 15,258 from 15,881 a year earlier — 623 fewer, or 3.9%. More clinics signed; fewer procedures ordered. The filing also publishes its own quarterly operating-margin series, 10.7%, 4.9%, 4.2%, 5.3% and 11.5% across the last five quarters, with the caveat that everything up to the fourth quarter of FY10/2025 is consolidated and everything from the first quarter of FY10/2026 is single-entity, so the series is not strictly comparable across that break. Adding up the four service lines quarter by quarter gives revenue of ¥816.5 million, ¥882.6 million and ¥858.4 million — so the margin more than doubled in the third quarter on slightly lower revenue than the second.

The profit is a cost result, and part of it is a one-off

Gross profit of ¥1,507 million on ¥2,557 million of revenue is a gross margin of 58.9%; SG&A of ¥1,328 million absorbs 51.9% of revenue, leaving an operating margin of 7.0%. The company's own account of the nine months is almost entirely about cost: it says it continued to optimise the allocation of management resources, executed further cost reductions centred on selling, general and administrative expenses, and reached a conclusion on which businesses to keep and concentrate on. Two extraordinary losses look like that decision being booked — ¥11.7 million of impairment and ¥2.4 million of store-withdrawal loss. It also says it co-developed a new exosome processing technology with a business partner, as planned at the start of the year. Below the operating line, ¥14.6 million of non-operating income met ¥19.6 million of non-operating expense, the largest single item being ¥11.9 million of losses on investment-partnership holdings. Extraordinary items then added a net ¥58.2 million and tax took ¥57.9 million back out, which is why net profit of ¥174.5 million lands within ¥0.4 million of ordinary profit. The merger gain alone is 28.2% of the ¥232.4 million of pre-tax profit, and it will not recur.

The guidance says the fourth quarter undoes the nine months

The full-year forecast was revised on the day of this filing. The company says it revised the FY10/2026 forecast it had published on July 29, 2026 in light of the nine-month result, and refers readers to a separate release issued the same day, "Notice of Revision to Earnings Forecast" — the reasoning is in that document, not in this one, and nothing in this filing supplies it. The revised year is revenue of ¥3,367 million, operating profit of ¥82 million, ordinary profit of ¥76 million and a net loss of ¥124 million, or a loss of ¥6.26 a share. Set against the nine months already reported, that arithmetic implies a fourth quarter of about ¥810 million of revenue — below each of the first three quarters — an operating loss of roughly ¥97 million and a net loss of roughly ¥298 million. The ¥201 million by which the implied net loss exceeds the implied operating loss is not explained anywhere in this document. The dividend forecast for the year is ¥0.00 against ¥5.00 paid for FY10/2025, but that is not a cut announced today: the revision flag on the dividend table reads "none", so the zero was already the standing forecast, and the filing gives no reason for it.

A balance sheet that is 68% cash

Total assets were ¥6,945 million, down ¥15.6 million over the nine months, of which ¥4,729 million — 68.1% — is cash and deposits, up ¥267.3 million. Tangible fixed assets fell ¥121.6 million to ¥867.2 million and shares in affiliates fell ¥200.0 million to nil, while intangibles rose. Liabilities fell ¥95.6 million to ¥877.8 million: the non-current provision for contract losses fell ¥62.0 million to ¥165.1 million and other provisions fell ¥48.2 million to ¥27.9 million, while the current portion of the contract-loss provision rose to ¥60.7 million from ¥36.5 million — so the total contract-loss provision fell to ¥225.8 million from ¥263.5 million, with part of what remains reclassified as due within a year. Net assets rose ¥80.0 million to ¥6,067 million, owners' equity to ¥5,958 million from ¥5,872 million, and the equity ratio improved to 85.8% from 84.4%. No quarterly cash-flow statement was prepared; the filing discloses depreciation of ¥133.5 million for the nine months, and the statements were not reviewed by an accounting auditor.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.